From the Gesund blog ·
From Lag to Live: The FDA's Real-Time Clinical Trial Initiative and What It Means for Health AI
A Gesund perspective on clinical-trial data flows and the implications for health AI evidence.
Read the latest article →Gesund Signal
Market intelligence by Gesund
Regulated AI.
In perspective.
The pulse of regulated healthcare AI: regulation, research, adoption and the companies moving the market. Actionable context for your next product and regulatory decision.
RegulationClinical evidenceAdoptionCompanies & competitionLifecycle & governance
Latest article
What’s worth your attention.
The Gesund blog now comes together here as Signal. Articles retain their original publication dates.
The Signal archive
Follow the market.
Inform the next move.
From Lag to Live: The FDA's Real-Time Clinical Trial Initiative and What It Means for Health AI
Enes Hosgor
Read the analysis →Inside the FDA's First Warning Letter Citing AI Misuse as a cGMP Violation
Enes Hosgor
Read the analysis →Paying for Intelligence: The Challenges and Opportunities of CMS Reimbursement for AI in Healthcare
Enes Hosgor
Read the analysis →FDA denied the Harrison.ai petition. The bigger signal is what comes next for clinical AI
Enes Hosgor
Read the analysis →FDA’s QMSR Is Live: Why Clinical AI Teams Need Inspection-Ready Evidence, Not Just Great Models
Enes Hosgor
Read the analysis →The FDA Radiology AI Debate Exposed the Next Big Gap in Clinical AI: Independent Lifecycle Validation
Enes Hosgor
Read the analysis →FDA’s AI PCCP Update: From August 2024 Baseline to AI Specific Submission Rules
Enes Hosgor
Read the analysis →State AI Laws Are Now Setting the Rules for Healthcare AI: Here’s What Colorado, Texas, Utah, Nevada, California and Others Actually Require
Enes Hosgor
Read the analysis →FDA’s New Regulatory Accelerator Forces a Rethink of AI Submission Strategy
Enes Hosgor
Read the analysis →AI Governance’s Bottom-Line Advantage: How Proactive Guardrails Deliver Measurable ROI in Regulated Healthcare
Enes Hosgor
Read the analysis →Navigating the Clinical State of the Art for SaMD: How to Avoid the Most Common Pitfalls
Enes Hosgor
Read the analysis →EU AI Act Is Now Law: What Healthcare AI Leaders Must Do in 2025
Enes Hosgor
Read the analysis →Medical Superintelligence Arrives: What Microsoft’s MAI DxO Means for Regulatory Grade Healthcare AI
Enes Hosgor
Read the analysis →First CE Certified Large Language Model for Clinical Decision Support: What Prof. Valmed’s Class IIb Approval Signals for Regulatory Grade Healthcare AI
Enes Hosgor
Read the analysis →The AMA & Manatt AI Governance Toolkit: A Blueprint for Responsible AI in Healthcare
Enes Hosgor
Read the analysis →FDA Ends Animal Testing: It’s not Just Ethical, It’s Strategic. Here’s What Comes Next for Pharma and AI
Enes Hosgor
Read the analysis →The FDA Is Now Using Generative AI to Review Drugs and Devices. Here’s What That Means for You.
Enes Hosgor
Read the analysis →The New Section 1557 Rule: AI Compliance in Healthcare Just Became a Strategic Imperative
Gesund.ai
Read the analysis →Biden and AI Governance: The Case for a Hub-and-Spoke Framework in Model Validation
Enes Hosgor
Read the analysis →Turn context into a decision
One change.
A clearer evidence question.
Use the change receipt to connect an AI update to its evidence, owners and next decision.
Use the change receipt →Bring one scenario.
Planning a clinical AI deployment or model update? Bring one scenario to a 20-minute evidence-readiness review.
Request a readiness review →